Table 1.
Baseline characteristics for participants (n=30,076) by treatment group
| Characteristic | Lisinopril | Amlodipine | Chlorthalidone | p-value* | ||
|---|---|---|---|---|---|---|
| Sample size by treatment | 8,189 | 8,112 | 13,775 | |||
| Age (y), mean (SD) | 66.8 (7.8) | 66.9 (7.7) | 66.8 (7.7) | 0.93 | ||
| Race, n (column %) | 0.86 | |||||
| White | 4,970 (60.7) | 4,916 (60.6) | 8,373 (60.8) | |||
| Black | 2,811 (34.3) | 2,808 (34.6) | 4,708 (34.2) | |||
| American Indian/Alaskan native | 18 (0.2) | 19 (0.2) | 27 (0.2) | |||
| Asian/Pacific Islander | 84 (1.0) | 96 (1.2) | 167 (1.2) | |||
| Other | 306 (3.7) | 273 (3.4) | 500 (3.) | |||
| Hispanic, n (%) | 1,626 (19.9) | 1,544 (19.0) | 2,696 (19.6) | 0.73 | ||
| Women, n (%) | 3,793 (46.3) | 3,864 (47.6) | 6,476 (47.0) | 0.24 | ||
| Previous antihypertensive treatment, n (%) | 7,373 (90.0) | 7,346 (90.6) | 12,426 (90.2) | 0.52 | ||
| Blood pressure, mm Hg: | ||||||
| All participants | ||||||
| SBP, mean (SD) | 146.6 (15.6) | 146.2 (15.7) | 146.3 (15.7) | 0.27 | ||
| DBP, mean (SD) | 84.2 (10.0) | 83.9 (10.2) | 84.1 (10.1) | 0.18 | ||
| Treated at baseline | ||||||
| SBP, mean (SD) | 145.5 (15.5) | 145.1 (15.6) | 145.2 (15.7) | 0.35 | ||
| DBP, mean (SD) | 83.6 (9.9) | 83.3 (10.0) | 83.5 (10.0) | 0.12 | ||
| Untreated at baseline | ||||||
| SBP, mean (SD) | 156.4 (12.4) | 156.5 (12.2) | 156.1 (12.0) | 0.68 | ||
| DBP, mean (SD) | 89.1 (9.3) | 89.7 (9.6) | 89.5 (9.0) | 0.46 | ||
| Eligibility risk factors: | ||||||
| Cigarette smoker, n (%) | 1,793 (21.9) | 1,792 (22.1) | 3,042 (22.1) | 0.94 | ||
| Type 2 diabetes, n (%) | 2,867 (35.0) | 2,954 (36.4) | 4,938 (35.9) | 0.17 | ||
| HDL-C < 35 mg/dL, n (%) | 963 (11.8) | 923 (11.4) | 1,650 (12.0) | 0.41 | ||
| LVH by electrocardiogram, n (%) | 1,325 (16.2) | 1,378 (17.0) | 2,219 (16.1) | 0.21 | ||
| BMI, kg/m2, mean (SD) | 29.8 (6.2) | 29.8 (6.3) | 29.7 (6.1) | 0.49 | ||
| Aspirin use, n (%) | 2,976 (36.3) | 2,950 (36.4) | 4,919 (35.7) | 0.59 | ||
| Fasting glucose, mg/dL, mean (SD) | 122.4 (55.9) | 122.9 (57.3) | 123.3 (58.5) | 0.62 | ||
| LDL cholesterol, mg/dL, mean (SD) | 135.9 (36.3) | 135.8 (37.3) | 136.0 (37.4) | 0.95 | ||
| HDL cholesterol, mg/dL, mean (SD) | 46.6 (14.6) | 47.1 (14.7) | 46.7 (14.9) | 0.06 | ||
| Fasting triglycerides, mg/dL, mean (SD) | 175.5 (138.9) | 176.9 (133.2) | 177.2 (132.6) | 0.67 | ||
| Glomerular filtration rate (GFR), mean (SD) | 77.7 (19.9) | 78.1 (19.6) | 77.6 (19.6) | 0.15 | ||
| FGB -455, n (column %) | 0.30 | |||||
| GG | 5,919 (72.3) | 5,817 (71.7) | 10,038 (72.9) | |||
| GA | 2,030 (24.8) | 2,029 (25.0) | 3,330 (24.2) | |||
| AA | 240 (2.9) | 266 (3.3) | 407 (3.0) | |||
SBP = systolic blood pressure, DBP = diastolic blood pressure, HDL-C = HDL cholesterol, LVH = left ventricular hypertrophy
*
test of differences between treatment groups: ANOVA for continuous variables, chi-square for categorical variables